Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.65)
# 796
Out of 5,240 analysts
82
Total ratings
57.35%
Success rate
26.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $652 → $649 | $518.87 | +25.08% | 10 | May 7, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $37 → $34 | $26.46 | +28.50% | 10 | Feb 18, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $62 → $74 | $52.75 | +40.28% | 3 | Feb 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $475 → $530 | $453.06 | +16.98% | 20 | Jan 23, 2026 | |
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $20 → $12 | $14.03 | -14.47% | 5 | Sep 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $280 → $515 | $291.48 | +76.70% | 2 | Sep 11, 2025 | |
| SVRA Savara | Maintains: In-Line | $3 → $2 | $5.27 | -62.05% | 5 | May 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $44.55 | +1.01% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $9.60 | +25.00% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $2.90 | +72.41% | 5 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $35 | $59.12 | -40.80% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $4.31 | -53.60% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $3.02 | +727.81% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $8.02 | +336.41% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $39.15 | -38.70% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $16.67 | +79.96% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $4.31 | +132.02% | 1 | Feb 5, 2020 |
Madrigal Pharmaceuticals
May 7, 2026
Maintains: Outperform
Price Target: $652 → $649
Current: $518.87
Upside: +25.08%
Ultragenyx Pharmaceutical
Feb 18, 2026
Maintains: Outperform
Price Target: $37 → $34
Current: $26.46
Upside: +28.50%
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Outperform
Price Target: $62 → $74
Current: $52.75
Upside: +40.28%
Vertex Pharmaceuticals
Jan 23, 2026
Maintains: Outperform
Price Target: $475 → $530
Current: $453.06
Upside: +16.98%
Enanta Pharmaceuticals
Sep 15, 2025
Maintains: Outperform
Price Target: $20 → $12
Current: $14.03
Upside: -14.47%
Alnylam Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $280 → $515
Current: $291.48
Upside: +76.70%
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $5.27
Upside: -62.05%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $44.55
Upside: +1.01%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $9.60
Upside: +25.00%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $2.90
Upside: +72.41%
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $59.12
Upside: -40.80%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $4.31
Upside: -53.60%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $3.02
Upside: +727.81%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $8.02
Upside: +336.41%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $39.15
Upside: -38.70%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $16.67
Upside: +79.96%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $4.31
Upside: +132.02%